SCHEMBL170734

SCHEMBL170734

C=CCS(=O)(=O)NC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28159469 0.84 KDM4E (0.31)
Sorbitol SCHEMBL10995011 0.82 LMNA (0.39)
SCHEMBL6887926 0.81
SCHEMBL1040932 0.77
SCHEMBL7109838 0.77
SCHEMBL6427762 0.76
SCHEMBL253162 0.75
SCHEMBL175854 0.75
SCHEMBL28386948 0.73
SCHEMBL6310315 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099953-A1 BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-12 US claimed
US-20180030019-A1 SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2018-02-01 US claimed
US-20180030017-A1 BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-02-01 US claimed
US-20180030056-A1 BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-02-01 US claimed
EP-2831066-B1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2016-10-05 EP claimed
WO-2016133963-A1 BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-25 WO claimed
WO-2016133972-A1 SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-25 WO claimed
WO-2016133961-A1 BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-25 WO claimed
WO-2016133970-A1 BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-25 WO claimed
US-9096580-B2 Benzofuran derivatives for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-04 US claimed
EP-1630157-A1 CaSR ANTAGONIST JAPAN TOBACCO INC. (JP) 2006-03-01 EP claimed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US claimed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US claimed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP claimed
EP-1278413-A2 N-ARYL-URACILE-BASED HERBICIDES Bayer CropScience AG (DE) 2003-01-29 EP claimed
WO-2001039597-A2 N-ARYL-URACILE-BASED HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2001-06-07 WO claimed
EP-1049376-A1 SELECTIVE HERBICIDES BASED ON N-ARYL- TRIAZOLINE(THI)ONS AND N-ARLYSULFONYLAMINO (THIO)CARBONYL- TRIAZOLINE(THI) ONS Bayer Aktiengesellschaft (DE) 2000-11-08 EP claimed
WO-1999037153-A1 SELECTIVE HERBICIDES BASED ON N-ARYL- TRIAZOLINE(THI)ONS AND N-ARLYSULFONYLAMINO (THIO)CARBONYL- TRIAZOLINE(THI) ONS BAYER AKTIENGESELLSCHAFT (DE) 1999-07-29 WO claimed
WO-1998027088-A1 HETEROCYCLYLURACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-06-25 WO claimed
US-4978672-A Alpha-heterocyclc substituted tolunitriles CIBA-GEIGY CORPORATION (US) 1990-12-18 US claimed